22-Oxa-1α,25-dihydroxyvitamin D 3 inhibits metastasis and angiogenesis in lung cancer
Open Access
- 17 February 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 26 (6) , 1044-1054
- https://doi.org/10.1093/carcin/bgi049
Abstract
1α,25-Dihydroxyvitamin D 3 (1α,25-D 3 ) has potent antiproliferative and anti-invasive properties in vitro in cancer cells. However, its calcemic effect in vivo limits its therapeutic applications. Here, we report the efficacy of 22-oxa-1α,25-dihydroxyvitamin D 3 (22-oxa-1α,25-D 3 ), a low calcemic analog of vitamin D, against the development of metastatic lung carcinoma after an intravenous injection of green fluorescent protein-transfected Lewis lung carcinoma (LLC-GFP) cells in C57BL/6 mice. The mice injected with tumor cells were implanted simultaneously with osmotic minipumps containing either 1α,25-D 3 , 22-oxa-1α,25-D 3 or vehicle. The 1α,25-D 3 treatment group had been hypercalcemic, but the 22-oxa-1α,25-D 3 and vehicle treatment groups remained normocalcemic for the duration of the experiment. The total number of lung metastases, lung weight and the expression of GFP mRNA in the lung were markedly decreased in 1α,25-D 3 and 22-oxa-1α,25-D 3 -treated mice. In the in vitro experiment, 1α,25-D 3 and 22-oxa-1α,25-D 3 reduced the expression of matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor and parathyroid hormone-related protein in LLC-GFP cells. Furthermore, in the angiogenesis assay, the number of tumor cells or basic fibroblast growth factor-induced angiogenesis was reduced in 1α,25-D 3 and 22-oxa-1α,25-D 3 -treated mice. Moreover, using a new experimental model of vitamin D receptor (VDR) null mutant ( VDR−/− ) mice with corrected hypocalcemia and hypervitaminosis D, we examine the anti-cancer effect of 22-oxa-1α,25-D 3 without other functions induced by 22-oxa-1α,25-D 3 in the host. In the VDR−/− mice, 22-oxa-1α,25-D 3 directly inhibited the metastatic activity of LLC-GFP cells in a dose-dependent manner without exerting a direct influence on the calcemic activity or other actions regulated by 22-oxa-1α,25-D 3 in the host. These results indicate that the inhibition of metastasis and angiogenesis-inducing activity in cancer cells seemed to be a major mechanism responsible for the anti-cancer effects of 22-oxa-1α,25-D 3 . Our findings show that 22-oxa-1α,25-D 3 is beneficial for the prevention of metastasis in lung carcinoma.Keywords
This publication has 40 references indexed in Scilit:
- 1 ,25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancerCarcinogenesis: Integrative Cancer Research, 2004
- Regulation of Extrarenal Vitamin D Metabolism as a Tool for Colon and Prostate Cancer PreventionPublished by Springer Nature ,2003
- Transcriptional Regulation of Vascular Endothelial Growth Factor Expression in Epithelial and Stromal Cells during Mouse Mammary Gland DevelopmentMolecular Endocrinology, 2001
- 1α,25-Dihydroxyvitamin D 3 Inhibits Angiogenesis In Vitro and In VivoCirculation Research, 2000
- Inhibition of tumor invasiveness by 1-alpha-25-dihydroxy-vitamin D coupled to a decline in protein kinase A activity and an increase in cytoskeletal organizationClinical & Experimental Metastasis, 1997
- Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrenceCancer Immunology, Immunotherapy, 1995
- The Binding Properties, with Blood Proteins, and Tissue Distribution of 22-Oxa-1α, 25-Dihydroxyvitamin D3, a Noncalcemic Analogue of 1α, 25-Dihydroxyvitamin D3, in Rats1The Journal of Biochemistry, 1994
- Antitumor effect of 22-oxa-1α,25-dihydroxyvitamin D3 a potent angiogenesis inhibitor, on rat mammary tumors induced by 7, 12-dimethylbenz[a]anthraceneAnti-Cancer Drugs, 1991
- A Novel Vitamin D3Analog, 22-Oxa-1, 25- Dihydroxyvitamin D3, Inhibits the Growth of Human Breast Cancerin Vitroandin Vivowithout Causing Hypercalcemia*Endocrinology, 1991
- Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton A trial of the development of vitamin D compounds which exhibit potent differentiation‐inducing activity without inducing hypercalcemiaFEBS Letters, 1987